Multimodal tongue and pulse assessment for diagnosing and tracking asthma in children

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center observational cohort will enroll children with confirmed asthma at Shanghai Children's Medical Center and collect standardized tongue images and pulse waveform data during outpatient visits when lung function testing is performed. Image processing and signal-analysis methods will extract quantitative features (color, texture, time- and frequency-domain pulse parameters) that will be integrated with clinical data such as asthma stage, spirometry, eosinophil counts, allergy status, and ACQ-5 scores. Data collection is noninvasive and performed under controlled conditions to ensure reproducibility without changing usual clinical care. The study aims to identify associations between multimodal tongue-pulse features and clinical phenotypes or disease control in pediatric asthma.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Children aged 5 to 18 years.
* Clinically diagnosed asthma according to established pediatric asthma guidelines.
* Receiving routine outpatient follow-up at Shanghai Children's Medical Center.
* Able to cooperate with tongue image acquisition and pulse wave data collection.
* Able to perform pulmonary function testing when clinically indicated.
* Written informed consent obtained from parents or legal guardians, with assent from the child when appropriate.

Exclusion Criteria:

* Presence of other chronic respiratory diseases (e.g., cystic fibrosis, bronchiectasis, primary ciliary dyskinesia).
* Congenital cardiopulmonary malformations or significant cardiovascular disease.
* Acute respiratory infection or fever at the time of data collection.
* Severe systemic diseases or immunodeficiency that may affect study participation.
* Inability to comply with study procedures or incomplete clinical data.

Where it's running

• Shanghai Children's Medical Center
  Shanghai, China Recruiting

Study contacts

• Principal investigator: Yong Yin — Shanghai Children's Medical Center
• Study coordinator: Yong Yin
• Email: yinyong9999@163.com
• Phone: 86-021-38626161

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Chronic Respiratory Disease Participant Engagement

  This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.

  Recruiting Richmond Pharmacology Limited · London · NCT07924462

• HB0056 in adults with moderate to severe asthma

  This study tests HB0056 versus a placebo to see if it helps adults with moderate to severe asthma reduce rescue inhaler use and improve symptoms.

  Recruiting at 2 sites Phase 1/2 Shanghai Huaota Biopharmaceutical Co., Ltd. · Beijing and 1 other locations · NCT07899996

• Tilrekimig (PF-07275315) for Severe Asthma: Aimed at Adults with Frequent Exacerbations

  This study tests whether tilrekimig helps people with severe asthma who have had multiple flare-ups in the past year, by comparing it to a placebo given every four weeks.

  Recruiting at 4 sites Phase 3 Pfizer · River Forest, Illinois and 11 other locations · NCT07869043

• Inhaled CHF10136 safety and pharmacokinetics in healthy adults and adults with asthma

  This first-in-human study tests inhaled CHF10136 to see if it is safe and well tolerated, how it behaves in the body, and how it affects adults with asthma compared with placebo.

  Recruiting Phase 1 Chiesi Farmaceutici S.p.A. · Leeds and 2 other locations · NCT07851623

• Biologics for Type 2 Inflammation in Asthma and COPD in Real World

  This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07823842

• GSK5784283 vs placebo in uncontrolled asthma (PERSIST ASTHMA-2)

  A new medicine called GSK5784283 is being tested to see if it lowers asthma flare-ups better than a placebo in people with uncontrolled asthma.

  Recruiting at 7 sites Phase 3 GlaxoSmithKline · San Diego, California and 6 other locations · NCT07782996

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.